This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutDosing & StorageOrdering & CodingSavings & SupportSavings and
SupportSupport and Resources

Co-Pay Assistance

Materials

VideosPfizer Commitment
Full Prescribing Information, including BOXED WARNINGSIndicationsPatient SiteExplore the Biosimilars Portfolio
About TRAZIMERA®
(trastuzumab-qyyp)TRAZIMERA® (trastuzumab-qyyp) is FDA approved across all indications of Herceptin® (trastuzumab)1ReferencesER=estrogen receptor; HER=human epidermal growth factor receptor; PR=progesterone receptor. High risk is defined as ER/PR positive with one of the following features: pathological tumor size >2 cm, tumor grade 2 to 3, or age <35 years.TRAZIMERA was approved by the FDA based on the totality of evidence demonstrating it is highly similar to Herceptin1,2ReferencesNCCN=National Comprehensive Cancer Network; PD=pharmacodynamic; PK=pharmacokinetic.NCCN Guidelines® recommend the use of an FDA-approved biosimilar as an appropriate substitute for trastuzumab. See the NCCN Guidelines for detailed recommendations, including specific treatment regimens. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.TRAZIMERA does not have a designation of interchangeability with Herceptin. FDA-approved biosimilars such as
trastuzumab-qyyp (TRAZIMERA®) are recommended as appropriate
substitutes for trastuzumab in the
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1,5,6†‡ TRAZIMERA has an identical dosing and administration schedule to Herceptin1 Learn More About Dosing Loading Get an in-depth look at TRAZIMERA with the product monograph Download LoadingReferences:TRAZIMERA [prescribing information]. New York, NY: Pfizer Inc.; November 2020.US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD: FDA, US Dept of Health and Human Services; April 2015. Accessed April 6, 2023. https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf.Data on file. Pfizer Inc.; New York, NY.US Food and Drug Administration. Center for Drug Evaluation and Research. Application Number: 761081Orig1s000 Trazimera Clinical Review(s). February 26, 2019. Accessed May 24, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761081Orig1s000MedR.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2023. © National Comprehensive Cancer Network, Inc. 2023.  All rights reserved. Accessed August 3, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.2.2023. © National Comprehensive Cancer Network, Inc. 2023.  All rights reserved. Accessed August 3, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.  TRAZIMERA is a registered trademark of Pfizer Inc.Herceptin® (trastuzumab) is a registered trademark of Genentech, Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TAS-USA-0231
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-TAS-USA-0206
INDICATIONSAdjuvant Breast CancerTRAZIMERA is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature*) breast cancer:
  • As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
  • As part of a treatment regimen with docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline based therapy
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

*High risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.Metastatic Breast Cancer

TRAZIMERA is indicated:

  • In combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.Metastatic Gastric CancerTRAZIMERA is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.Please see full Prescribing Information, including BOXED WARNINGS.
Important Safety Information BOXED WARNINGS AND ADDITIONAL IMPORTANT SAFETY INFORMATION Cardiomyopathy
  • Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens
  • Evaluate left ventricular function in all patients prior to and during treatment with TRAZIMERA. Discontinue TRAZIMERA treatment in patients receiving adjuvant therapy and withhold TRAZIMERA in patients with metastatic disease for clinically significant decrease in left ventricular function
 Infusion Reactions; Pulmonary Toxicity
  • Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt TRAZIMERA infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue TRAZIMERA for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome
 Embryo-Fetal Toxicity
  • Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception
 Cardiomyopathy
  • Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy
  • Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death
  • Trastuzumab products can also cause asymptomatic decline in LVEF
  • Discontinue TRAZIMERA treatment in patients receiving adjuvant breast cancer therapy and withhold TRAZIMERA in patients with metastatic disease for clinically significant decrease in left ventricular function
 Cardiac Monitoring
  • Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of TRAZIMERA
  • Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan
  • Monitor frequently for decreased left ventricular function during and after TRAZIMERA treatment
  • Monitor more frequently if TRAZIMERA is withheld for significant left ventricular cardiac dysfunction
 Infusion Reactions
  • Administration of trastuzumab products can result in serious and fatal infusion reactions
  • Symptoms usually occur during or within 24 hours of administration of trastuzumab products
  • Interrupt TRAZIMERA infusion for dyspnea or clinically significant hypotension
  • Monitor patients until symptoms completely resolve
  • Discontinue TRAZIMERA for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Strongly consider permanent discontinuation in all patients with severe infusion reactions
  • Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion include nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia
 Embryo-Fetal Toxicity
  • Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception
  • Verify the pregnancy status of females of reproductive potential prior to the initiation of TRAZIMERA
  • Advise pregnant women and females of reproductive potential that exposure to TRAZIMERA during pregnancy or within 7 months prior to conception can result in fetal harm
  • Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of TRAZIMERA
  • Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for TRAZIMERA treatment and any potential adverse effects on the breastfed child from TRAZIMERA or from the underlying maternal condition
 Pulmonary Toxicity
  • Administration of trastuzumab products can result in serious and fatal pulmonary toxicity, which includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, noncardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactions
  • Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity
  • Discontinue TRAZIMERA in patients experiencing pulmonary toxicity
 Exacerbation of Chemotherapy-Induced Neutropenia
  • In randomized, controlled clinical trials, the numbers of per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not
 Most Common Adverse Reactions
  • The most common adverse reactions associated with trastuzumab products in breast cancer were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia
  • The most common adverse reactions associated with trastuzumab products in metastatic gastric cancer were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia
IndicationsAdjuvant Breast Cancer

TRAZIMERA is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature*) breast cancer:
  • As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
  • As part of a treatment regimen with docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline based therapy
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

*High risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.Metastatic Breast Cancer

TRAZIMERA is indicated:
  • In combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.Metastatic Gastric Cancer

TRAZIMERA is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.Please see full Prescribing Information, including BOXED WARNINGS.